IDO1 and neoplasm: There was no difference in expression or activation of IDO, GCN2, or mTOR pathway in CD45− LLCs (Supplementary Figure S6), suggesting that the IDO-deficient immune cells are responsible for altered Trp signaling rather than the tumor cells.